All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

February 26th 2024

McKesson has received approval from the CMS to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.

Tislelizumab Receives CHMP Recommendation for First- and Second-Line Treatment of NSCLC

February 26th 2024

The European Medicines Agency’s CHMP has recommended the approval of tislelizumab in the first- and second-line for non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to BAY 2927088 for HER2-Mutated NSCLC

February 26th 2024

BAY 2927088 has received breakthrough therapy designation by the FDA for pretreated non–small cell lung cancer harboring activating HER2 mutations.

Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC

February 26th 2024

Benjamin Philip Levy, MD, details how antibody-drug conjugates are shifting the HER2-mutated non–small cell lung cancer treatment paradigm.

Further Validation Required If AI Models Are to Revolutionize GI Cancer Care

February 26th 2024

Jacob Shreve, MD, MS, highlights the intersection between artificial intelligence and personalized medicine, as well as its potential utility in gastrointestinal cancers.

Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD

February 25th 2024

Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.

Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers

February 24th 2024

Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.

Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies

February 24th 2024

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.

FDA Confirms Decision to Withdraw Melphalan Flufenamide Approval in Multiple Myeloma

February 23rd 2024

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

Belumosudil Plus Ruxolitinib Displays Activity in Steroid-Refractory/-Dependent cGVHD

February 23rd 2024

Belumosudil plus ruxolitinib elicited responses with acceptable tolerability in patients with chronic graft-vs-host disease.

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

February 23rd 2024

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL

February 23rd 2024

Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Concomitant Azoles Does Not Affect Clinical Outcomes With Ruxolitinib in Acute GVHD

February 23rd 2024

Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.

Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma

February 23rd 2024

Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.

Ruxolitinib Plus Belumosudil Boosts Responses in Chronic GVHD

February 23rd 2024

Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.

Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD

February 23rd 2024

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

In Judo Move, Scientists Use Cancer’s Strength to Fight Against It

February 23rd 2024

A genetic mutation that makes cancer cells hardy can be engineered into T cells, giving them superhuman strength.

Perioperative Pembrolizumab Regimen Receives Positive CHMP Opinion in NSCLC

February 23rd 2024

Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.

Luspatercept Receives Positive EU CHMP Opinion for Treatment of Anemia in Lower-Risk MDS

February 23rd 2024

Luspatercept has been recommended for approval by the EMA for patients with transfusion-dependent anemia and lower-risk myelodysplastic syndromes.